Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
- 20 March 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (7) , 1903-1910
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the general population. The NAFLD spectrum ranges from simple steatosis to cirrhosis. The chemokine CCL5/RANTES plays an important role in the progression of hepatic inflammation and fibrosis. The objective of this study was to examine the effects of maraviroc, a CCR5 antagonist, on liver pathology in a NAFLD mouse model. A total of 32 male C57BL/6 mice were randomly assigned to one of four groups: (i) control group (chow diet plus tap water); (ii) maraviroc group (chow diet plus maraviroc in drinking water); (iii) high-fat diet (HFD) group (HFD plus tap water); and (iv) maraviroc/HFD group (HFD plus maraviroc). All mice were sacrificed 16 weeks after the beginning of the experiment. Biochemical analyses and liver examinations were performed. Mice in the HFD group showed a tendency towards increased body mass gain and liver damage compared with the maraviroc/HFD group. Moreover, liver weight in the HFD group was significantly higher than in the maraviroc/HFD group. Hepatic triglyceride concentration in the maraviroc/HFD group was significantly lower than in the HFD group. Interestingly, the maraviroc/HFD group exhibited a lower degree of steatosis. Furthermore, hepatic CCL5/RANTES expression was significantly lower in the maraviroc/HFD group than in the HFD group. Overall, no differences were observed between the control group and the maraviroc group. Maraviroc ameliorates hepatic steatosis in an experimental model of NAFLD.Keywords
This publication has 41 references indexed in Scilit:
- Inflammation-Induced Hepatocellular Carcinoma Is Dependent on Ccr5 in MiceHepatology, 2013
- Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse ModelPLOS ONE, 2013
- Human Fatty Liver Disease: Old Questions and New InsightsScience, 2011
- Clinical use of CCR5 inhibitors in HIV and beyondJournal of Translational Medicine, 2011
- Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse ModelPLOS ONE, 2010
- Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in miceJournal of Clinical Investigation, 2010
- Functional role of chemokines in liver disease modelsNature Reviews Gastroenterology & Hepatology, 2010
- Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese PatientsPLOS ONE, 2010
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005